# Gilead Sciences, Inc. (GILD) — Q1-2023 Earnings Results

**Report date:** 2023-04-27 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q1-2023

## Post-Earnings Brief

### Headline

Gilead Sciences Misses on EPS, Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.37 | N/A | -15.85% |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management acknowledged the current hurdles but remains focused on future growth opportunities. They are committed to navigating the competitive landscape.

**Key quotes:**

> Management highlighted ongoing challenges in the market but expressed confidence in long-term strategies.

> They emphasized the importance of upcoming product launches.

### Guidance Changes

No guidance data is available for this quarter.

### What It Means

This earnings report indicates that Gilead Sciences faced challenges in meeting earnings expectations, with a notable EPS miss. The lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, but the management's cautious optimism suggests they are focused on overcoming current market difficulties.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q1-2023_